Introduction
============

Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide. In 2012, there were \~782,500 new cases and \~745,500 incidences of mortality owing to liver cancer, with China alone making up \~50% of this number ([@b1-ol-0-0-7860]). One issue in HCC management frequently confronted by hepatologist is the accurate prediction of survival outcome, which is necessary in order to provide optimal medical care. A number of staging systems, including clinical Tumor-Node-Metastasis (TNM) stage ([@b2-ol-0-0-7860]), Cancer of the Liver Italian Program (CLIP) ([@b3-ol-0-0-7860]) and Barcelona Clinic Liver Cancer (BCLC) ([@b4-ol-0-0-7860]), are used to predict the prognosis of HCC and stratify patients for treatment. However, patient outcome may be associated not only with disease stage, but also with biological factors. With recent developments in the fields of genomics and proteomics, more relevant prognostic factors are yet to be identified to improve the prognostic strategy of HCC.

In previous genome-wide microarray analysis, a series of genes, including ATP-dependent DNA helicase Q4 (RECQL4), disks large-associated protein 5 ([@b5-ol-0-0-7860]) and family with sequence similarity 83 member D ([@b6-ol-0-0-7860]), were significantly upregulated in HCC tissues. RECQL4, as one of the human DNA helicases, serves a critical role in genomic instability and aging processes ([@b7-ol-0-0-7860]). Genome instability is deemed to have an important part in the multistep development of human cancer ([@b8-ol-0-0-7860]). Furthermore, interaction has been observed between RECQL4 and proteins involved in genome surveillance ([@b9-ol-0-0-7860]). Previous studies have demonstrated that mutations in RECQL4 cause three autosomal recessive diseases, Rothmund-Thomson, Rapadilino and Baller-Gerold syndromes ([@b10-ol-0-0-7860]--[@b12-ol-0-0-7860]). The potential for unlimited replication is a hallmark of cancer cells ([@b8-ol-0-0-7860]). RECQL4 serves an essential role in the initiation of DNA replication ([@b13-ol-0-0-7860]--[@b15-ol-0-0-7860]) and is directly or indirectly involved in multiple DNA repair pathways, through interactions with diverse repair proteins ([@b16-ol-0-0-7860]--[@b18-ol-0-0-7860]). Several studies have revealed that increased RECQL4 expression is observed in sporadic osteosarcoma, prostate carcinogenesis and breast tumorigenesis ([@b19-ol-0-0-7860]--[@b21-ol-0-0-7860]). Therefore, the role of RECQL4 in human cancer, including HCC, necessitates further investigation.

The aims of the present study were to detect RECQL4 expression in HCC tissue, evaluate the association between RECQL4 expression and patient clinicopathological features and the prognostic significance of RECQL4 expression in HCC.

Materials and methods
=====================

### Specimens

A total of 205 pairs of fresh HCC tissues and corresponding adjacent normal liver tissues (ANLT) were obtained from HCC patients who underwent radical curative surgery at the Affiliated Hospital of Guilin Medical University (Guilin, China) between March 2001 and September 2007. The mean age of the patients was 50.22 years (range, 21--74 years). The diagnosis of HCC was based on the results of clinical symptoms, serological, ultrasonography (US), computed tomography, magnetic resonance imaging, pathological examination, according to the primary liver cancer clinical diagnosis and staging criteria. The baseline information, shown in [Table I](#tI-ol-0-0-7860){ref-type="table"}, includes age, gender, family history, hepatitis B surface antigen (HBsAg), a-fetoprotein (AFP), cirrhosis, tumor size and number, BCLC disease stage, metastasis and recurrence. All samples were snap-frozen in liquid nitrogen and stored at −80°C immediately following surgical resection. The inclusion criteria of the present study were as follows: i) Samples were confirmed to be HCC by pathological examination, and the patients underwent radical resection; ii) all patients enrolled have complete background information and follow-up records, including periodic review of liver function, AFP value, imaging information, recurrence time and treatment regimen. Patients diagnosed with cholangiocarcinoma or those that suffered perioperative mortality or with incomplete clinical data were excluded. Additionally, patients who suffered from infectious diseases, autoimmune disease, hematologic disease or used drugs that affect the hematopoietic system within 1 month prior to starting treatment, HIV-positive patients and those who lost contact in the follow-up period were excluded.

The present study was approved by the Ethics Committee of The Affiliated Hospital of Guilin Medical University (Guilin, China) and complies with the Ethical Guidelines of the Declaration of Helsinki. All patients provided written informed consent prior to investigation.

Following surgical resection, the patients with HCC received long-term follow-up via monitoring of serum AFP levels and US examination every 2 months, a chest radiograph every 6 months during the first 2 postoperative years and at 3--6-month intervals thereafter. Computerized tomography or magnetic resonance imaging would be performed if the result of AFP test or US examination were abnormal. Disease-free survival (DFS) time was measured from the date of surgery to the date of recurrence, metastasis, mortality or the last follow-up. Overall survival (OS) time was measured from the date of surgery to the date of death or last follow-up.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from HCC frozen tissue samples using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) reagent, and cDNA was synthesized by using PrimeScript RT reagent kit (Takara Bio, Inc., Otsu, Japan) according to the manufacturer\'s instructions. The temperature protocol of reverse transcription was as follows: 42°C for 2 min in order to remove the contamination of genomic DNA, then reverse transcription at 37°C for 15 min and 85°C for 5 sec. qPCR analysis was performed using SYBR Premix Ex Taq (Takara Bio, Inc., Otsu, Japan), according to the manufacturer\'s instructions. Each well was mixed with 15 µl Master Mix (SYBR^®^ Green PCR Master Mix; Applied Biosystems; Thermo Fisher Scientific, Inc.). The protocol was performed with an initial denaturation step at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 2 sec, annealing at 55°C for 5 sec and extension at 72°C for 15 sec. The sequences of the primers used were: RECQL4 (158 bp) forward, 5′-TCAACATGAAGCAGAAACACTAC-3′ and reverse, 5′-CTGCTCGTTCAGGAAACAAGACT-3′; and β-actin (142 bp) forward, 5′-GACAGGATGCAGAAGGAGATTACT-3′ and reverse, 5′-TGATCCACATCTGCTGGAAGGT-3′. The levels of RECQL4 were normalized to the levels of β-actin expression using the 2^−ΔΔCq^ methodas reported by Livak and Schmittgen ([@b22-ol-0-0-7860]).

### Statistical analysis

All quantitative data are expressed as the mean ± standard deviation and were analyzed using an independent t-test. Categorical variables were compared using χ^2^ test. The DFS and OS rates were calculated using the Kaplan-Meier method, and comparisons of survival curves between groups were assessed with log-rank test. Multivariate analysis was performed using the Cox proportional hazards model, and only variables that were statistically significant in univariate analysis were included in this model. All statistical analyses were performed using SPSS13.0 statistical software (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression of RECQL4 mRNA is upregulated in human HCC tissues

RECQL4 mRNA expression was examined in 205 samples of fresh HCC tissues and their corresponding ANLT by RT-qPCR. As shown in [Fig. 1A](#f1-ol-0-0-7860){ref-type="fig"}, the relative expression of RECQL4 mRNA in HCC cancer tissues (1.10±0.07) was significantly higher compared with ANLT (0.33±0.04) when normalized to β-actin (P\<0.001). The RECQL4 mRNA levels were increased in 141 cases (68.8%), but decreased in 64 cases (31.2%). Notably, the upregulation of RECQL4 mRNA expression and the increase of serum AFP levels did not completely overlap. High RECQL4 expression along with high serum AFP level was detected in 96 cases (46.83%), high serum AFP level alone was detected in 34 cases (16.59%), and upregulation of RECQL4 but not AFP was detected in 45cases (21.95%; [Fig. 1B](#f1-ol-0-0-7860){ref-type="fig"}). These results indicated that RECQL4 might be a novel histological biomarker for HCC. When these two markers were combined, the HCC diagnosis rate was increased to 85.37%.

### Association between RECQL4 mRNA and clinical pathological characteristics of HCC

To further investigate the association between RECQL4 mRNA expression and clinicopathological parameters of HCC, the characteristics of the 205 HCC patients were analyzed. As shown in [Table I](#tI-ol-0-0-7860){ref-type="table"}, the level of RECQL4 mRNA expression was positively associated with AFP level (\>100 ng/ml) (χ^2^=4.246, P=0.039), tumor size (\>6 cm) (χ^2^=7.852, P=0.005), and BCLC stage (χ^2^=6.293, P=0.012), but was not associated with age (\>55 years), gender, family history, alcohol consumption, HBsAg expression, liver cirrhosis, tumor number, metastasis or postoperative recurrence (all P\>0.05).

### Univariate analysis of prognostic factors of DFS and OS

Kaplan-Meier survival analysis revealed that patients expressing high levels of RECQL4 mRNA had significantly shorter DFS and OS times compared with those with low RECQL4 mRNA expression (log-rank test: P=0.002, and P=0.001, respectively; [Fig. 2](#f2-ol-0-0-7860){ref-type="fig"}). Mean DFS and OS in the high-RECQL4 mRNA expression group was 34.23 months \[95% confidence interval (CI), 28.42--40.03\] and 38.37 months (95% CI, 32.84--43.90) respectively, compared with 50.73 months (95% CI, 41.88--59.58) and 56.31 months (95% CI, 48.33--64.30) in the low-RECQL4 mRNA expression group (P=0.002 and P=0.001, respectively; [Table II](#tII-ol-0-0-7860){ref-type="table"}). Apart from high RECQL4 mRNA expression, other factors, including size of tumor (\>6 cm), multiple tumor number, stage B-C (according to BCLC staging) and metastasis, were also strongly associated with a shorter DFS and OS, and recurrence was associated with a shorter OS ([Table II](#tII-ol-0-0-7860){ref-type="table"}).

### Multivariate analysis of independent predictors on DFS and OS

To evaluate the predictive roles of these factors in HCC prognosis further (other than recurrence factor, which was measured only for OS), high RECQL4 mRNA expression and other clinical pathological parameters \[size of tumor (\>6 cm), multiple tumor number, BCLC stage B-C and metastasis\] that were identified to be statistically significant by univariate analysis were analyzed using the multivariate Cox proportional hazards model for DFS and OS. Cox multivariate analysis revealed that high RECQL4 mRNA expression (HR, 1.635; 95% CI, 1.062--2.515; P=0.025), as well as size of tumor (\>6 cm) (HR, 2.670; 95% CI, 1.704--4.183; P\<0.001), BCLC stage B-C (HR, 1.835; 95% CI, 1.116--3.018; P=0.017) were independent predictors for DFS ([Table III](#tIII-ol-0-0-7860){ref-type="table"}). High RECQL4 mRNA expression (HR, 1.618; 95% CI, 1.050--2.493; P=0.029), size of tumor (\>6 cm) (HR, 2.536; 95% CI, 1.621--3.967; P\<0.001), BCLC stage B-C (HR,1.679; 95% CI, 1.128--2.760; P=0.041) and disease recurrence (HR, 2.832; 95% CI, 1.827--4.391; P\<0.001) were independent predictors for OS ([Table III](#tIII-ol-0-0-7860){ref-type="table"}).

Discussion
==========

RECQL4 expression is associated with cancer-prone syndromes and premature aging. RECQL4 shares homology in its N-terminal domain with the yeast replication initiation protein Sld2, which participates in DNA replication initiation ([@b13-ol-0-0-7860]--[@b15-ol-0-0-7860],[@b23-ol-0-0-7860],[@b24-ol-0-0-7860]). Unlimited replicative potential is a hallmark of HCC cells. In the present study, the expression of RECQL4 mRNA was investigated in HCC tissues, and RECQL4 mRNA was found to be highly expressed in liver cancer tissues compared with ANLT. Similar to other oncogenes, overexpression of RECQL4 may confer an unlimited proliferative potential to hepatoma cells and promote hepatocellular tumorigenesis ([@b20-ol-0-0-7860],[@b21-ol-0-0-7860]).

The upregulation of RECQL4 mRNA expression in HCC tissues was positively associated with serum AFP levels (\>100 ng/ml). Despite being a recommended tumor marker for HCC screening, detecting AFP alone is not optimal for the surveillance or diagnosis of HCC, owing to its deficiencies in the sensitivity and specificity of testing ([@b25-ol-0-0-7860]). Therefore, the identification of novel molecular markers with superior sensitivity and specificity is urgently required. The present study indicated that RECQL4 maybe a potential novel biomarker for HCC diagnosis, and the positive rate of HCC diagnosis may be improved to 85.37% by detecting a combination of AFP and RECQL4. In addition, the increase in the level of RECQL4 mRNA expression was also positively associated with large tumor size (\>6 cm) and stage B-C disease. Therefore, the authors hypothesize that RECQL4 contributes to malignant progression of HCC.

Under univariate analysis, high RECQL4 expression, tumor size \>6 cm, multiple tumor nodules, metastasis and stage B-C disease were identified to associate with poor DFS and OS times of HCC patients. Large tumors (\>5 cm) and multiple tumors are more closely associated with bilobar tumor involvement, tumor invasion of adjacent organs, microvascular invasion and histologically positive margins ([@b26-ol-0-0-7860]). In addition, tumor size (\>5 cm) and multinodular disease were reported to significantly increase the risk of postoperative recurrence ([@b26-ol-0-0-7860]--[@b28-ol-0-0-7860]). The data from the present study demonstrated that intermediate and advanced BCLC stage is predictive of a poorer prognosis for HCC patients following surgical resection. For HCC patients who received no anticancer treatment, the severity of the BCLC stage is strongly consistent with a poorer median survival as well ([@b29-ol-0-0-7860]). Notably, high RECQL4 mRNA expression in HCC patients was also predictive of a significantly shorter survival compared with patients with low RECQL4 expression. These clinical data suggest that RECQL4 maybe a useful prognostic marker for HCC.

In the present study, notable predictive factors of survival for HCC were identified. High RECQL4 expression, size of tumor \>6 cm, and stage B-C disease were shown to be independent predictors of DFS and OS for HCC patients. Large tumor size (\>5 cm) has been consistently shown to be an independent prognostic marker in HCC patients ([@b30-ol-0-0-7860],[@b31-ol-0-0-7860]). Generally, HCC patients with larger tumors (\>6 cm) have a poorer prognosis. Since an inaccurate prediction can bring about severe harm to patients, as independent predictors for the outcomes of HCC, the expression of RECQL4, tumor size and BCLC stage can aid hepatologists in providing more accurate prognosis predictions, improved risk assessment assessing and in planning therapeutic trials.

In conclusion, the results of the current study found that the expression of RECQL4 mRNA was significantly higher in HCC tissue compared with adjacent normal liver tissues. Whether the upregulation of RECQL4 expression contributes to hepatocarcinogenesis will be a key research question to be investigated in future experiments. It may be possible to use RECQL4 as a novel biomarker for HCC diagnosis. This retrospective study also provides evidence that RECQL4 may serve as an independent predictor of prognosis for HCC patients. Furthermore, targeting RECQL4 may provide a promising strategy for the treatment of HCC patients with high RECQL4 expression. However, further research is required to elucidate the underlying molecular mechanism of HCC.
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![Level of RECQL4 mRNA expression in HCC tissues and ANLT. (A) Reverse transcription-quantitative polymerase chain reaction analysis of RECQL4 was performed on 205 paired HCC cancer tissues and ANLT. The levels of RECQL4 mRNA expression were scored and compared. For each sample, the relative RECQL4 mRNA level was normalized to the level of β-actin. (B) The distribution of RECQL4 mRNA and serum AFP levels in the 205 HCC specimens. The percentage of specimens with high and low RECQL4 expression and AFP-positive expression are indicated. HCC, hepatocellular carcinoma; ANLT, adjacent normal liver tissues; RECQL4, ATP-dependent DNA helicase Q4; AFP, α-fetoprotein.](ol-15-04-4248-g00){#f1-ol-0-0-7860}

![Association between RECQL4 expression and DFS or OS. Kaplan-Meier analysis revealed significantly shorter (A) DFS and (B) OS times in patients with hepatocellular carcinoma with high RECQL4 expression compared with patients with low RECQL4 expression. The solid line represents patients with low RECQL4 expression, and the dashed line represents patients with high RECQL4 expression. OS, overall survival; DFS, disease-free survival; RECQL4, ATP-dependent DNA helicase Q4.](ol-15-04-4248-g01){#f2-ol-0-0-7860}

###### 

Association between clinicopathological characteristics and RECQL4 mRNA expression in HCC.

                               RECQL4 expression                         
  --------------------- ------ ------------------- ------------- ------- -------
  Age, years                                                     0.448   0.503
    ≤55                 138    41 (29.7)             97 (70.3)           
    \>55                  67   23 (34.3)             44 (65.7)           
  Sex                                                            0.892   0.345
    Male                172    56 (32.6)           116 (67.4)            
    Female                33     8 (24.2)            25 (75.8)           
  Family history                                                 0.082   0.775
    No                  172    53 (30.8)           119 (69.2)            
    Yes                   33   11 (33.3)             22 (66.7)           
  Alcohol consumption                                            0.554   0.457
    No                  101    34 (33.7)             67 (66.3)           
    Yes                 104    30 (28.8)             74 (71.2)           
  HBsAg                                                          1.454   0.228
    Negative              41   16 (39.0)             25 (61.0)           
    Positive            164    48 (29.3)           116 (70.7)            
  AFP, ng/ml                                                     4.246   0.039
    ≤100                  75   30 (40.0)             45 (60.0)           
    \>100               130    34 (26.2)             96 (73.8)           
  Cirrhosis                                                      2.715   0.099
    No                    20     3 (15.0)            17 (85.0)           
    Yes                 185    61 (33.0)           124 (67.0)            
  Tumor size, cm                                                 7.852   0.005
    ≤6                    89   37 (41.6)             52 (58.4)           
    \>6                 116    27 (23.3)             89 (76.7)           
  Tumor number                                                   0.509   0.475
    Single              137    45 (32.8)             92 (67.2)           
    Multiple              68   19 (27.9)             49 (72.1)           
  BCLC stage                                                     6.293   0.012
    0-A                   92   37 (40.2)             55 (59.8)           
    B-C                 113    27 (23.9)             86 (76.1)           
  Metastasis                                                     0.789   0.374
    No                  176    57 (32.4)           119 (67.6)            
    Yes                   29     7 (24.1)            22 (75.9)           
  Recurrence                                                     1.737   0.188
    No                  135    38 (28.1)             97 (71.9)           
    Yes                   70   26 (37.1)             44 (62.9)           

RECQL4, ATP-dependent DNA helicase Q4; HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; Metastasis, distant metastasis or lymph node metastasis.

###### 

Association between RECQL4 mRNA expression, clinical parameters and disease-free/overall survival.

                               Disease-free survival   Overall survival                                    
  --------------------- ------ ----------------------- ------------------ --------- ------- -------------- ---------
  RECQL4 mRNA                                                             0.002                            0.001
    Low                   64   50.73                   41.88--59.58                 56.31   48.33--64.30   
    High                141    34.23                   28.42--40.03                 38.37   32.84--43.90   
  Age, years                                                              0.646                            0.634
    ≤55                 138    38.09                   32.06--44.11                 43.70   37.84--49.57   
    \>55                  67   40.68                   32.17--49.19                 45.85   37.62--54.08   
  Sex                                                                     0.299                            0.141
    Female                33   45.30                   31.98--58.63                 53.41   41.20--65.62   
    Male                172    37.82                   32.53--43.10                 42.81   37.63--47.50   
  Family history                                                          0.155                            0.115
    No                  172    37.20                   31.90--42.50                 42.85   37.65--48.06   
    Yes                   33   48.00                   35.61--60.39                 53.12   41.56--64.68   
  Alcohol consumption                                                     0.139                            0.081
    No                  101    43.60                   36.17--51.04                 48.07   41.02--55.13   
    Yes                 104    34.88                   28.50--41.26                 40.51   34.20--46.81   
  HBsAg                                                                   0.652                            0.616
    Negative              41   35.44                   25.01--45.87                 41.84   31.60--52.09   
    Positive            164    39.74                   34.18--45.30                 44.61   39.30--49.93   
  AFP, ng/ml                                                              0.200                            0.209
    ≤100                  75   42.88                   35.17--50.58                 48.09   40.94--55.24   
    \>100               130    37.19                   30.73--43.65                 41.20   35.06--47.34   
  Cirrhosis                                                               0.694                            0.824
    No                    20   35.40                   19.79--51.01                 41.85   27.14--56.56   
    Yes                 185    39.23                   34.05--44.14                 44.24   39.27--49.21   
  Tumor size, cm                                                          \<0.001                          \<0.001
    ≤6                    89   57.76                   50.66--64.85                 62.66   56.55--68.77   
    \>6                 116    25.25                   19.59--30.91                 29.59   24.04--35.14   
  Tumor number                                                            \<0.001                          \<0.001
    Single              137    44.85                   38.77--50.92                 50.84   45.03--56.65   
    Multiple              68   26.57                   19.03--34.11                 31.75   24.25--39.25   
  BCLC stage                                                              \<0.001                          \<0.001
    0-A                   92   54.29                   47.04--61.54                 60.09   53.47--66.72   
    B-C                 113    26.41                   20.70--32.12                 31.76   25.94--37.58   
  Metastasis                                                              0.023                            0.048
    No                  176    41.15                   35.76--46.53                 45.63   40.51--50.75   
    Yes                   29   23.56                   14.71--32.42                 34.12   22.84--45.39   
  Recurrence                                                                                               \<0.001
    No                  135                                                         34.55   28.81--40.28   
    Yes                   70                                                        63.22   56.70--69.75   

CI, confidence interval; HBsAg, hepatitis B surfaceantigen; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; Metastasis, distant metastasis or lymph node metastasis; RECQL4, ATP-dependent DNA helicase Q4.

###### 

Cox multivariate proportional hazards model of independent predictors on disease-free and overall survival.

  A, Disease-free survival                                    
  ------------------------------------ ---------------------- -------------
  Tumor size, cm (≤6 vs. \>6 cm)       2.670 (1.704--4.183)   \<0.001
  Tumor number (single vs. multiple)   1.092 (0.692--1.723)   0.707
  Metastasis (no vs. yes)              1.116 (0.685--1.816)   0.660
  BCLC stage (0-A vs. B-C)             1.835 (1.116--3.018)   0.017
  RECQL4 mRNA (low vs. high)           1.635 (1.062--2.515)   0.025
                                                              
  **B, Overall survival**                                     
                                                              
  **Parameter**                        **HR (95% CI)**        **P-value**
                                                              
  Tumor size, cm (≤6 vs. \>6 cm)       2.536 (1.621--3.967)   \<0.001
  Tumor number (single vs. multiple)   1.033 (0.652--1.637)   0.890
  Metastasis (no vs. yes)              1.212 (0.742--1.981)   0.443
  BCLC stage (0-A vs. B-C)             1.679 (1.021--2.760)   0.041
  Recurrence (no vs. yes)              2.832 (1.827--4.391)   \<0.001
  RECQL4 mRNA (low vs. high)           1.618 (1.050--2.493)   0.029

HR, hazard ratio; CI, confidence interval; metastasis, distant metastasis or lymph node metastasis; BCLC, Barcelona Clinic Liver Cancer; RECQL4, ATP-dependent DNA helicase Q4.
